Bydgoszcz

• DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of car … Ended recruitment
  2023-505210-18-00 5 2021-12-17 Early stage HER2-positive breast cancer (T stage >= T3, lymph node pos
• Efficacy and Safety of Selumetinib in Adults with NF1 who have Symptomatic, Inoperable Plexiform Neurofibromas. Ended recruitment
  2023-507336-20-00 5 2021-12-08 Neurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform
• A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receivin … Ended recruitment
  2023-505695-30-00 5 2021-11-30 systemic lupus erythematosus
• A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance … Ended recruitment
  2023-509133-39-00 5 2021-11-29 Hormone receptor positive, HER2-negative advanced breast cancer
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended recruitment
  2023-506518-33-00 5 2021-11-10 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Efficacy of Abatacept vs Adalimumab in Early, Autoantibody positive Rheumatoid Arthritis (RA) and who did not respond well to methotrexate. Ended recruitment
  2023-506450-20-00 5 2021-11-05 Rheumatoid Arthritis
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus (ALLEGORY) Ended recruitment
  2023-504774-38-00 5 2021-11-04 Systemic Lupus Erythematosus (SLE)
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic … Ended recruitment
  2023-506257-37-00 5 2021-10-29 Active Psoriatic Arthritis
• A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended recruitment
  2023-503990-39-00 5 2021-09-30 Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
• MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex … Ended recruitment
  2023-509208-14-00 5 2021-09-28 MULTIPLE MYELOMA
• A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended recruitment
  2023-506368-14-00 5 2021-09-07 Systemic lupus erythematosus (SLE)
• A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended recruitment
  2023-504734-21-00 5 2021-08-30 Psoriatic arthritis (PsA)
• Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive Participants Ended recruitment
  2023-504716-15-00 6 2021-08-06 Psoriatic Arthritis
• Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children with Neurofibro … Ended recruitment
  2024-517216-29-00 3 2021-08-06 Neurofibromatosis Type 1 (NF1) Related Plexiform Neurofibromas (PN)
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic … Ended recruitment
  2023-506752-24-00 5 2021-08-05 Locally recurrent inoperable or metastatic HR+/HER2- breast cancer, wh
• Study of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Given with Chemotherapy, to Treat Metastatic Squamous or Non Squamous … Ended recruitment
  2023-508308-40-00 5 2021-07-30 Metastatic (stage IV) squamous or nonsquamous non-small cell lung canc
• Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended recruitment
  2022-502856-29-00 7 2021-07-27 Advanced Solid Tumors
• A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended recruitment
  2023-507697-40-00 5 2021-07-05 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas … Ended recruitment
  2024-517253-27-00 5 2021-07-01 Acute lymphoblastic leukemia
• Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello- … Ended recruitment
  2023-504997-39-00 5 2021-06-14 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
• Long-term safety of apraglutide in short bowel syndrome Ended recruitment
  2023-510389-28-00 5 2021-06-14 short bowel syndrome
• An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended recruitment
  2022-502122-41-00 5 2021-05-11 Clear cell renal cancer
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended recruitment
  2023-507132-21-00 10 2021-05-11 Early Parkinson's disease

Showing 457–480 of 707 trials